Literature DB >> 10419833

High-level expression and purification of biologically active recombinant pokeweed antiviral protein.

F Rajamohan1, C R Engstrom, T J Denton, L A Engen, I Kourinov, F M Uckun.   

Abstract

Pokeweed antiviral protein (PAP) from the leaves of the pokeweed plant, Phytolacca americana, is a naturally occurring single-chain ribosome-inactivating protein, which catalytically inactivates both prokaryotic and eukaryotic ribosomes. The therapeutic potential of PAP has gained considerable interest in recent years due to the clinical use of native PAP as the active moiety of immunoconjugates against cancer and AIDS. The clinical use of native PAP is limited due to inherent difficulties in obtaining sufficient quantities of a homogenously pure and active PAP preparation with minimal batch to batch variability from its natural source. Previous methods for expression of recombinant PAP in yeast, transgenic plants and Escherichia coli have resulted in either unacceptably low yields or were too toxic to the host system. Here, we report a successful strategy which allows high level expression of PAP as inclusion bodies in E. coli. Purification of refolded recombinant protein from solubilized inclusion bodies by size-exclusion chromatography yielded biologically active recombinant PAP (final yield: 10 to 12 mg/L). The ribosome depurinating in vitro N-glycosidase activity and cellular anti-HIV activity of recombinant PAP were comparable to those of the native PAP. This expression and purification system makes it possible to obtain sufficient quantities of biologically active and homogenous recombinant PAP sufficient to carry out advanced clinical trials. To our knowledge, this is the first large-scale expression and purification of biologically active recombinant PAP from E. coli. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10419833     DOI: 10.1006/prep.1999.1084

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  6 in total

1.  Structure-based design and engineering of a nontoxic recombinant pokeweed antiviral protein with potent anti-human immunodeficiency virus activity.

Authors:  Fatih M Uckun; Francis Rajamohan; Sharon Pendergrass; Zahide Ozer; Barbara Waurzyniak; Chen Mao
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

2.  Type 1 ribosome-inactivating proteins from Phytolacca dioica L. leaves: differential seasonal and age expression, and cellular localization.

Authors:  Augusto Parente; Barbara Conforto; Antimo Di Maro; Angela Chambery; Paolo De Luca; Andrea Bolognesi; Marcello Iriti; Franco Faoro
Journal:  Planta       Date:  2008-08-13       Impact factor: 4.116

3.  Inhibition of hepatitis B virus replication by pokeweed antiviral protein in vitro.

Authors:  Yong-Wen He; Chun-Xia Guo; Yan-Feng Pan; Cheng Peng; Zhi-Hong Weng
Journal:  World J Gastroenterol       Date:  2008-03-14       Impact factor: 5.742

4.  CNS activity of Pokeweed anti-viral protein (PAP) in mice infected with lymphocytic choriomeningitis virus (LCMV).

Authors:  Fatih M Uckun; Larisa Rustamova; Alexei O Vassilev; Heather E Tibbles; Alexander S Petkevich
Journal:  BMC Infect Dis       Date:  2005-02-22       Impact factor: 3.090

Review 5.  Pokeweed antiviral protein, a ribosome inactivating protein: activity, inhibition and prospects.

Authors:  Artem V Domashevskiy; Dixie J Goss
Journal:  Toxins (Basel)       Date:  2015-01-28       Impact factor: 4.546

6.  Detection of cystatin C biomarker for clinical measurement of renal disease by developed ELISA diagnostic kits.

Authors:  Renren Jiang; Chao Xu; Xiaoli Zhou; Tianhao Wang; Gang Yao
Journal:  J Transl Med       Date:  2014-09-12       Impact factor: 5.531

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.